search
Back to results

Blood Cell Collection for Future Use in Individuals With Fanconi Anemia

Primary Purpose

Fanconi Anemia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PBSC Collection
Bone Marrow Harvest
CliniMacs Cell Selection System
Sponsored by
National Heart, Lung, and Blood Institute (NHLBI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fanconi Anemia

Eligibility Criteria

1 Year - 35 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of FA Normal bone marrow cytogenetics within 3 months of study entry Absolute neutrophil count (ANC) level greater than 750 Hemoglobin level greater than 8 without transfusion Platelet level greater than 30,000 without transfusion Must weigh at least 7.5 kg Exclusion Criteria: Myloid or lymphoid leukemia Cytogenic abnormalities HIV infected Neoplastic or non-neoplastic disease of any major organ system that would compromise the ability to withstand the collection procedure Uncontrolled infection Unable to tolerate general anesthesia Known adverse reaction to E. Coli Pregnant or breastfeeding

Sites / Locations

  • Cincinnati Children's Hospital Medical Center

Outcomes

Primary Outcome Measures

CD34+ cell collection

Secondary Outcome Measures

Full Information

First Posted
December 29, 2005
Last Updated
July 11, 2016
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators
Children's Hospital Medical Center, Cincinnati
search

1. Study Identification

Unique Protocol Identification Number
NCT00271089
Brief Title
Blood Cell Collection for Future Use in Individuals With Fanconi Anemia
Official Title
Collection of Hematopoietic Cells From Patients With Fanconi Anemia (FA) for Future Autologous Reinfusion and Research
Study Type
Interventional

2. Study Status

Record Verification Date
December 2007
Overall Recruitment Status
Completed
Study Start Date
August 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators
Children's Hospital Medical Center, Cincinnati

4. Oversight

5. Study Description

Brief Summary
Fanconi anemia (FA) is a disease that affects an individual's bone marrow. It is caused by a defective gene in the CD34+ cells, which are responsible for producing various types of blood cells. Individuals with FA may experience fatigue, bleeding, and increased infections. The purpose of this study is to collect and purify blood cells from individuals with FA and store them for future therapeutic use.
Detailed Description
FA is a rare, inherited disease that is caused by a gene defect to the CD34+ cells. It primarily affects an individual's bone marrow, resulting in decreased production of blood cells. The lack of white blood cells affects an individual's ability to fight infections, the lack of platelets may result in bleeding, and the lack of red blood cells usually leads to anemia. FA is typically diagnosed in childhood, and there is a high fatality rate. This study will use two methods to collect, purify, and store participant's CD34+ cells for future use in case of severe bone marrow failure. The collected cells will also be used by researchers to better understand the causes of FA and to possibly develop new treatments. This study will enroll individuals with FA. All participants will undergo a bone marrow biopsy within 3 months of study entry. Based on the results of this biopsy, participants will undergo either a bone marrow harvest procedure or a cytokine mobilized peripheral blood stem cell (PBSC) collection procedure. Prior to both procedures, medical history will be reviewed, blood will be drawn, liver and kidney function will be evaluated, and a physical examination will be performed. Participants who undergo the bone marrow harvest procedure will be admitted to the hospital, with a possible overnight stay for observation. The following day, participants will have a physical examination and blood draw for laboratory testing. A blood and/or platelet transfusion may be required following the procedure. Participants who undergo the PBSC procedure will be required to receive injections of G-CSF, a protein found normally in the body, twice a day for 4 to 8 days prior to the procedure; G-CSF has been found to help increase the amount of CD34+ cells in the blood. Once the CD34+ level is within a certain range, the PBSC procedure will begin through an IV placed in the arm or a temporary collection catheter placed under the participants' collarbone. Blood cells will be collected, with some cells separated out and the remainder of the cells infused back into the participant. The length of this procedure will vary for each participant; it will take 3 to 6 hours a day, for 1 to 4 days. Participants may require blood and/or platelet transfusions prior to and during the procedure. Following the bone marrow harvest and PBSC procedures, CD34+ cells will be isolated in a laboratory. The majority of the cells will be frozen and stored for future use by the participants. A small portion of the cells will be available for researchers to perform experimental research to better understand FA. The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fanconi Anemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
PBSC Collection
Intervention Type
Procedure
Intervention Name(s)
Bone Marrow Harvest
Intervention Type
Device
Intervention Name(s)
CliniMacs Cell Selection System
Primary Outcome Measure Information:
Title
CD34+ cell collection

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of FA Normal bone marrow cytogenetics within 3 months of study entry Absolute neutrophil count (ANC) level greater than 750 Hemoglobin level greater than 8 without transfusion Platelet level greater than 30,000 without transfusion Must weigh at least 7.5 kg Exclusion Criteria: Myloid or lymphoid leukemia Cytogenic abnormalities HIV infected Neoplastic or non-neoplastic disease of any major organ system that would compromise the ability to withstand the collection procedure Uncontrolled infection Unable to tolerate general anesthesia Known adverse reaction to E. Coli Pregnant or breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stella Davies, MBBS
Organizational Affiliation
Children's Hospital Medical Center, Cincinnati
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
17164793
Citation
Kelly PF, Radtke S, von Kalle C, Balcik B, Bohn K, Mueller R, Schuesler T, Haren M, Reeves L, Cancelas JA, Leemhuis T, Harris R, Auerbach AD, Smith FO, Davies SM, Williams DA. Stem cell collection and gene transfer in Fanconi anemia. Mol Ther. 2007 Jan;15(1):211-9. doi: 10.1038/sj.mt.6300033.
Results Reference
background

Learn more about this trial

Blood Cell Collection for Future Use in Individuals With Fanconi Anemia

We'll reach out to this number within 24 hrs